Loading clinical trials...
Loading clinical trials...
Co-Developing a Women-Centered HIV Prevention Intervention to Reduce Stigma, Increase HIV Self-Testing, and Improve PrEP Awareness and Uptake in Ghana
The WISE Woman Study is a research project in Ghana focused on improving HIV prevention among young women aged 18 to 35. In Ghana, young women are at higher risk of HIV but often lack access to the right information and services. This study will first work with young women and community partners to co-develop a youth-friendly and women-centered HIV prevention program. The program will focus on two proven strategies: HIV self-testing (HIVST) and pre-exposure prophylaxis (PrEP), a medicine that helps prevent HIV. After the program is created, researchers will test it with 50 young women in Greater Accra and the Eastern Region to see if it's acceptable, easy to use, and if it helps increase knowledge and use of HIVST and PrEP. The intervention will be delivered through WhatsApp and community-based workshops to ensure privacy and reach. Participants will complete surveys and take part in discussions and interviews to share their feedback. This research will help build better HIV prevention strategies tailored to the needs of young women in Ghana.
Young women in Ghana face some of the highest risks of HIV infection in the country, yet they often lack access to HIV prevention tools and supportive services that are tailored to their needs. Many of the barriers they face-including stigma, low awareness, and limited youth-friendly options-can prevent them from accessing HIV self-testing (HIVST) or pre-exposure prophylaxis (PrEP), which are proven prevention methods. The WISE Woman Study seeks to address these barriers by engaging young women as equal partners in the design and implementation of an HIV prevention intervention. The study is based on the idea that solutions are more effective when they are created with the community, not for it. It uses participatory methods to involve young women in shaping the intervention and includes two main phases: Phase 1 - Co-Development Workshop: Fifteen participants-including ten young women and five community stakeholders (such as healthcare workers or peer educators)-will take part in a full-day participatory workshop. During this workshop, they will identify key barriers to HIV prevention, co-create solutions, and help design the structure of the intervention. Structured methods such as the Nominal Group Technique (NGT) and Human-Centered Design (HCD) will be used to ensure that all voices are heard and that the final program reflects the participants' preferences and lived experiences. Phase 2 - Pilot Study: Fifty young women aged 18-35 will participate in a 4-week pilot study to test the feasibility and acceptability of the co-developed intervention. Participants will receive information, support, and discussion prompts through WhatsApp-a platform commonly used in Ghana. They will complete short surveys before and after the intervention, and a subset will take part in in-depth interviews to reflect on their experiences. The study will look at changes in knowledge and attitudes toward HIV prevention, willingness to use HIVST and PrEP, and whether participants feel more empowered to take charge of their sexual health. This study is designed with privacy, respect, and participant safety in mind. By using a mobile platform and focusing on community co-creation, the WISE Woman Study offers an innovative approach to strengthening HIV prevention among young women in Ghana. The findings will help inform future HIV programs and may serve as a model for youth-centered public health interventions in similar settings.
Age
18 - 35 years
Sex
FEMALE
Healthy Volunteers
Yes
EARC
Accra, Ghana
Start Date
July 1, 2025
Primary Completion Date
December 30, 2026
Completion Date
December 30, 2026
Last Updated
January 26, 2026
65
ESTIMATED participants
Women-Centered HIV Prevention Program
BEHAVIORAL
Lead Sponsor
State University of New York at Buffalo
NCT07292792
NCT07002866
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06889831